ClinicalTrials.gg
RecruitingNCT07799688Updated Oct 9, 2026

A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia

A Phase 2 interventional study of HRS-7249 Injection and HRS-7249 Injection in Hyperlipidemia, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants. Cohort 1 includes subjects who completed parent study HRS-7249-201 within 24 weeks; Cohort 2 newly recruited patients with fasting triglyceride (TG) ≥2.3 mmol/L aged 18-79 years. All participants receive subcutaneous HRS-7249 for a 48-week treatment period followed by a 24-week safety follow-up phase, with two dosing regimens. The primary objective is to assess long-term safety and tolerability of repeated HRS-7249 administration. Secondary objectives include evaluating sustained lipid-lowering effects on TG, APOC3 and other lipid profiles, impacts on glycometabolism, incidence of acute pancreatitis and major adverse cardiovascular events (MACE), long-term pharmacokinetic/pharmacodynamic (PK/PD) profiles, and anti-drug antibody (ADA) dynamics. All safety assessments including vital signs, physical examinations, laboratory tests, 12-lead ECG, injection site reactions and adverse events will be collected throughout the study. Lipid parameters, HbA1c, pancreatitis and cardiovascular events will be monitored to characterize the clinical benefit-risk profile of long-term HRS-7249 therapy in hypertriglyceridemia patients. A total of at least 400 subjects will be enrolled nationwide in China.

02

Conditions studied

  • Hyperlipidemia

Browse trials for

03

In context

Hyperlipidemias

861 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.

This study's planned enrollment of 400 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.

Browse Hyperlipidemias studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Cohort 1 (Roll-over participants from HRS-7249-201)

  1. Able to understand trial procedures, voluntarily participate and provide written ;
  2. Completed last visit of parent study HRS-7249-201 within 24 weeks prior to screening;
  3. Male or female subjects aged ≥18 and \<80 years at consent signature. Cohort 2 (Newly enrolled participants)

1. Able to understand trial procedures, voluntarily participate and provide written informed consent; 2. Fasting triglyceride ≥2.3 mmol/L at screening; 3. Male or female subjects aged ≥18 and \<80 years at consent signature.

Exclusion criteria

Exclusion Criteria:

- Cohort 1 Exclusion

  1. Permanently discontinued parent study treatment due to treatment-related adverse events (TRAE);
  2. Persistent adverse events or lab abnormalities unresolved by parent study final visit, judged by investigator to increase risk of continued dosing;
  3. Unstable or severe hepatic, renal, cardiovascular, neurological, endocrine, hematologic disorders that render participation unacceptable;
  4. Plan to receive major surgery during study period;
  5. Planned plasmapheresis during trial;
  6. Intend to use weight-loss drugs or undergo weight-altering surgery during trial;
  7. Refuse lifestyle intervention or limit daily alcohol intake below 30 g/day;
  8. Pregnant or breastfeeding females;
  9. Fertile women without within 30 days pre-screening; fertile male/female subjects refusing contraception and gamete donation restrictions through follow-up;
  10. Any other conditions judged unsuitable by investigator. Cohort 2 Exclusion

1. History of acute pancreatitis within 3 months pre-randomization; 2. Plasmapheresis received or planned within 4 weeks pre-randomization; 3. diagnosed within past 5 years (except cured non-melanoma skin cancer/cervical carcinoma in situ); 4. Class III/IV heart failure at screening/randomization; 5. Acute coronary syndrome, stroke, , major cardiovascular revascularization within past 3 months; 6. Severe symptomatic arrhythmia within 3 months pre-randomization; 7. Severe trauma/major surgery within 6 months or planned major operation during trial; 8. Severe infection within past 3 months; 9. Nephrotic syndrome, severe liver disease, Cushing syndrome interfering with lipid metabolism; 10. Unstable severe multi-organ systemic diseases; 11. Uncontrolled hypertension (SBP≥160 mmHg or DBP≥100 mmHg); 12. Plan to take weight-loss agents or bariatric surgery within 2 months pre-screening; 13. Type 1 DM, newly diagnosed DM within 12 weeks, or ≥8.5%; 14. Current/history hyper/hypothyroidism; 15. History of substance/alcohol abuse (daily ethanol >80 g); 16. Major lifestyle modification within past 4 weeks or refusal of alcohol/lifestyle limits; 17. \<60 mL/min/1.73m² by MDRD formula; 18. /AST ≥2×; 19. Total/direct ≥1.5×ULN; 20. CK >1.5×ULN; 21. count \<100×10⁹/L or thrombocytopenia history; 22. Positive /-Ab, or positive with HBV-DNA ≥1000 copies/mL; 23. Participated in other interventional drug trials within 3 months pre-screening; 24. Pregnant or lactating women; 25. Fertile subjects without compliant contraception; 26. Any other conditions deemed inappropriate by investigator.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Arm 1

    HRS-7249 Injection; Low dose, subcutaneous administration

    Drug: HRS-7249 Injection

  • Experimental
    Arm 2

    HRS-7249 Injection; High dose, subcutaneous administration

    Drug: HRS-7249 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Injection site reactions

    Time frame: 48 weeks

  2. All adverse events (AEs)

    Time frame: 72 weeks

  3. Respiratory rate

    Time frame: 72 weeks

  4. Pulse rate

    Time frame: 72 weeks

  5. Systolic and diastolic blood pressure

    Time frame: 72 weeks

  6. Body temperature

    Time frame: 72 weeks

  7. Complete Blood Count

    Time frame: 72 weeks

  8. Blood chemistry

    Time frame: 72 weeks

  9. High-sensitivity C-reactive protein (hs-CRP)

    Time frame: 72 weeks;

  10. Heart rate

    Time frame: 72 weeks;

  11. PR interval

    Time frame: 72 weeks

  12. QRS duration

    Time frame: 72 weeks

  13. QT interval

    Time frame: 72 weeks

  14. QTc interval

    Time frame: 72 weeks

  15. Urinalysis

    Time frame: 72 weeks

Secondary outcomes

  1. Proportion of patients with TG<1.7 mmol/L

    Time frame: 48 weeks

  2. Proportion of patients with TG<2.3 mmol/L

    Time frame: 48 weeks

  3. Proportion of patients with baseline TG≥5.7 mmol/L achieving TG<5.7 mmol/L

    Time frame: 48 weeks

  4. Percentage change and absolute value change from baseline in TG

    Time frame: 72 weeks

  5. Percentage change and absolute value change from baseline in APOC3

    Time frame: 72 weeks

  6. Percentage change and absolute value change from baseline in HDL-C

    Time frame: 72 weeks

  7. Percentage change and absolute value change from baseline in TC

    Time frame: 72 weeks

  8. Percentage change and absolute value change from baseline in LDL-C

    Time frame: 72 weeks

  9. Percentage change and absolute value change from baseline in sdLDL-C

    Time frame: 72 weeks

  10. Percentage change and absolute value change from baseline in non-HDL-C

    Time frame: 72 weeks

  11. Percentage change and absolute value change from baseline in ApoB

    Time frame: 72 weeks

  12. Percentage change and absolute value change from baseline in ApoA1

    Time frame: 72 weeks

  13. Percentage change and absolute value change from baseline in Lp(a)

    Time frame: 72 weeks

  14. Percentage change and absolute value change from baseline in VLDL-C

    Time frame: 72 weeks

  15. Percentage change and absolute value change from baseline in RC

    Time frame: 72 weeks

  16. Percentage change and absolute value change from baseline in HbA1c

    Time frame: 72 weeks

  17. Incidence rate of acute pancreatitis

    Time frame: 72 weeks

  18. Incidence rate of major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina, or coronary revascularization)

    Time frame: 72 weeks

  19. Plasma Concentration of long-term HRS-7249 treatment

    Time frame: 72 weeks

  20. Dynamics of anti-drug antibody (ADA) following long-term HRS-7249 treatment

    Time frame: 72 weeks

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of Shandong First Medical University (Qianfo Shan Hospital of shandong province).
    Jinan, Shandong 250014, China
    Recruiting
    • Mei Gao · Principal investigator
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • Xumin Hou · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2028, 25 months after the start.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2026
First posted
Sep 2, 2026
StartActual
Sep 11, 2026
Primary completionEst.
Oct 15, 2028
CompletionEst.
Oct 15, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • The First Affiliated Hospital of Shandong First Medical University (Qianfo Shan Hospital of shandong province). · Jinan, Chinano status→Recruiting
  • Shanghai Chest Hospital · Shanghai, Chinano status→Recruiting
Oct 9, 2026
Start date
Sep 30, 2026→Sep 11, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • The First Affiliated Hospital of Shandong First Medical University (Qianfo Shan Hospital of shandong province). · Jinan, Chinano status→Recruiting
    • Shanghai Chest Hospital · Shanghai, Chinano status→Recruiting
    Start date Sep 30, 2026→Sep 11, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07799688
Responsible party
Sponsor
First posted
Sep 2, 2026
Start date
Sep 11, 2026
Primary completion
Oct 15, 2028 (estimated)
Completion
Oct 15, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Chanjuan Deng, MM
Contact
Chanjuan.deng@hengrui.com
0518-82342973
Jianpeng Su, MS
Contact
jianpeng.su.js18@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7249

Start the discussion